ArticleBMC cancer2019
Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.Breast cancer research and treatment · 2021Trial
- Survival prediction in triple-negative breast cancer: a Cox model with fairness assessment using ISO/IEC TR 24027:2021 in a MENA cohort.Exploration of targeted anti-tumor therapy · 2026Article
- Development of predictive models for the prognosis of triple-negative breast cancer using multiple transcriptomic analyses.PloS one · 2026Article
- Deep learning for survival prediction in triple-negative breast cancer: development and validation in real-world cohorts.Scientific reports · 2025Article
- Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy.Scientific reports · 2025Article
- Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer.Frontiers in surgery · 2025Article
- Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.Therapeutic advances in medical oncology · 2025Article
- Development and validation of a nomogram for predicting cancer-specific survival in small-bowel adenocarcinoma patients using the SEER database.World journal of surgical oncology · 2024Article
- Specific mortality in patients with diffuse large B-cell lymphoma: a retrospective analysis based on the surveillance, epidemiology, and end results database.European journal of medical research · 2024Article
- Development and validation of a nomogram for predicting rapid relapse in triple-negative breast cancer patients treated with neoadjuvant chemotherapy.Frontiers in cell and developmental biology · 2024Article
- Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer.Frontiers in oncology · 2023Article
- Article
- Nomogram for predicting overall survival in Chinese triple-negative breast cancer patients after surgery.World journal of clinical cases · 2022Article
- Survival outcome assessment for triple-negative breast cancer: a nomogram analysis based on integrated clinicopathological, sonographic, and mammographic characteristics.European radiology · 2022Article
- Development and validation of a Surveillance, Epidemiology, and End Results (SEER)-based prognostic nomogram for predicting survival in gastric cancer with multi-organ metastases.Translational cancer research · 2022Article
- Distant Metastasis Pattern and Prognostic Prediction Model of Colorectal Cancer Patients Based on Big Data Mining.Frontiers in oncology · 2022Article
- The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.Frontiers in oncology · 2022Article
- A Nomogram Based on Hematological Parameters and Clinicopathological Characteristics for Predicting Local-Regional Recurrence After Breast-Conserving Therapy.Frontiers in oncology · 2022Article
- Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making.Breast (Edinburgh, Scotland) · 2021Article
- Nomograms predict survival of patients with small bowel adenocarcinoma: a SEER-based study.International journal of clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTriple negative breast cancer (TNBC) is an aggressive and heterogeneous disease. Nomograms predicting outcomes of TNBC are needed for risk management.
methodsNomograms were based on an analysis of 296 non-metastatic TNBC patients treated at Sun Yat-sen Memorial Hospital from 2002 to 2014. The end points were disease-free survival (DFS) and overall survival (OS). Predictive accuracy and discriminative ability were evaluated by concordance index (C-index), area under the curve (AUC) and calibration curve, and compared with the American Joint Committee on Cancer (AJCC) staging system, PREDICT and CancerMath. Models were subjected to bootstrap internal validation and external validation using independent cohorts of 191 patients from the second Xiangya Hospital and Peking University Shenzhen Hospital between 2007 and 2012.
resultsOn multivariable analysis of training cohort, independent prognostic factors were stromal tumor-infiltrating lymphocytes (TILs), tumor size, node status, and Ki67 index, which were then selected into the nomograms. The calibration curves for probability of DFS and OS showed optimal agreement between nomogram prediction and actual observation. The C-index of nomograms was significantly higher than that of the seventh and eighth AJCC staging system for predicting DFS (training: 0.743 vs 0.666 (P = 0.003) and 0.664 (P = 0.024); validation: 0.784 vs 0.632 (P = 0.02) and 0.607 (P = 0.002)) and OS (training: 0.791 vs 0.683 (P = 0.004) and 0.677 (P < 0.001); validation: 0.783 vs 0.656 (P = 0.006) and 0.606 (P = 0.001)). Our nomograms had larger AUCs compared with PREDICT and CancerMath. In addition, the nomograms showed good performance in stratifying different risk groups of patients both in the training and validation cohorts.
conclusionWe have developed novel and practical nomograms that can provide individual prediction of DFS and OS for TNBC based on stromal TILs, tumor size, node status, and Ki67 index. Our nomograms may help clinicians in risk consulting and selection of long term survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.